| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2647 | Icl-sirt078 | Novel highly selective, substrate-competitive SIRT2 inhibitor, displaying a significant neuroprotective effect in a lactacystin-induced model of Parkinsonian neuronal cell death in the N27 cell line |
|
| DCC2648 | Icpd62 | Novel inhibitor of heat shock protein 90 (Hsp90), demonstrating anticancer activity against colorectal, osteosarcoma and cervical cancer cell lines |
|
| DCC2649 | Icrf-193 | DNA topoisomerase II inhibitor |
|
| DCC2650 | Ict2700 | Potent cytotoxin selectively by CYP1A1 as a tumor-selective treatment for human bladder cancers |
|
| DCC2651 | Id110460001 | Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
| DCC2652 | Id110460002 | Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
| DCC2653 | Id110460003 | Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
| DCC2654 | idaverine | M1 and M2 Antagonist |
|
| DCC2655 | Ide-in-37 Tfa Salt | Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
| DCC2656 | Ide-in-63 Tfa Salt | Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
| DCC2657 | Idh2 Inhibitor | Novel isocitrate dehydrogenase 2 (IDH2) mutants inhibitor for the treatment of cancer |
|
| DCC2658 | Idi-3783 | Novel mutant-selective Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor |
|
| DCC2659 | Ido1/2 Inhibitor 4t | The first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM) |
|
| DCC2660 | idoxifene | Selective ER modulator (SERM) |
|
| DCC2661 | Idr-0081053 | Novel bactericidal agent against M. tuberculosis under acidic conditions, being effective at sterilizing cultures in a concentration-dependent fashion at the highest concentrations |
|
| DCC2662 | Idr-0099118 | Novel concentration dependent bactericidal agent against M. tuberculosis, being markedly more efficient at killing M. tuberculosis under acidic conditions |
|
| DCC2663 | Idr-1002 | Innate Defence Regulator Peptide, Enhancing Monocyte Migration and Adhesion on Fibronectin |
|
| DCC2664 | Idr-1018 Tfa Salt | Novel immunomodulatory and antibiofilm innate defense regulator peptide |
|
| DCC2665 | Idrapril | Angiotensin converting enzyme (ACE) inhibitor |
|
| DCC2666 | Iferanserin | Selective serotonin 5-HT2A receptor antagonist |
|
| DCC2667 | Ifn-1 Inducer C3 | Novel Type I Interferon Inducer |
|
| DCC2668 | Ifn-1 Inducer E51 | Novel Type I Interferon Inducer |
|
| DCC2669 | Ifn-1 Inducer L56 | Novel Type I Interferon Inducer; Intercalator of DNA; Inhibitor of the retrovirus replications including HIV |
|
| DCC2670 | Igf2bp2/imp2 Inhibitor 4 | First Small-Molecule Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
| DCC2671 | Igf2bp2/imp2 Inhibitor 6 | Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
| DCC2672 | Igf2bp2/imp2 Inhibitor 9 | Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
| DCC2673 | Iglu-antagonist-21a | Highly potent fluorescent iGlu receptor antagonist |
|
| DCC2674 | Ihr-saha | Novel dual SMO-HDAC antagonist, retaining similar specificity for SAHA-targeted HDACs, disabling deviant Hedgehog signaling and preventing GLI binding to DNA |
|
| DCC2675 | Ikarugamycin | Natural Inhibitor of Clathrin-Mediated Endocytosis |
|
| DCC2676 | Ikkß-in-124 | Novel allosteric inhibitor of IκBα phosphorylation and NF-κB transcriptional activity through selective capture of the inactive conformation and hence blockade of IKKβ S177/S181 phosphorylation |
|
